Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Laura Lawrence

Reproductive Endocrinology Dallas, TX Medical Doctor

NPI 1346284627 CMS profile 600515

5477 Glen Lakes Drive, Suite 200, Dallas, TX 75231

Open in the dashboard

General payments

$2,863

209 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Lawrence of Dallas, TX is reported in the CMS Open Payments database as having received $2,863 across 209 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $347 27
2024 General $457 34
2023 General $449 36
2022 General $420 35
2021 General $443 30
2020 General $260 17
2019 General $487 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Lawrence
  • Reproductive Endocrinology median
  • Middle half of Reproductive Endocrinology
  • National median

In program year 2025, general payments to Laura Lawrence were reported at $347. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.

Show as a table
Year Laura Lawrence Reproductive Endocrinology median Middle half National median
2019 $487 $196 $77–$425 $163
2020 $260 $81 $35–$182 $114
2021 $443 $102 $43–$247 $132
2022 $420 $139 $62–$303 $149
2023 $449 $141 $65–$285 $160
2024 $457 $144 $65–$302 $164
2025 $347 $141 $66–$285 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ferring Pharmaceuticals Inc. $1,161 112 payments
  2. Organon LLC $510 36 payments
  3. Merck Sharp & Dohme Corporation $237 15 payments
  4. AbbVie, Inc. $219 14 payments
  5. EMD Serono, Inc. $197 10 payments
  6. CooperSurgical, Inc. $116 2 payments
  7. Astellas Pharma US Inc $111 2 payments
  8. Meditrina $69 4 payments
  9. Mission Pharmacal Company $53 4 payments
  10. Hologic, LLC $38 2 payments
  11. Other $152 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,777 206 payments
  2. Education $86 3 payments
Products named General payments · program years 2019–2025
  1. MENOPUR Reproductive Health $789 76 payments
  2. PREGNYL $447 32 payments
  3. FOLLISTIM AQ Follitropin $389 26 payments
  4. MENOPUR Reproductive Health $372 36 payments
  5. GANIRELIX ACETATE Ganirelix Acetate $323 24 payments
  6. FOLLISTIM AQ Womens Health $225 14 payments
  7. Orilissa $149 9 payments
  8. GANIRELIX ACETATE Womens Health $136 9 payments
  9. Veozah $111 2 payments
  10. IVF Products $99 1 payment
  11. Other $466 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

209 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record